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TO THE EDITOR
Genomic amplification is a frequent aberration in malignant
proliferation that usually leads to an inappropriate expression of
one or more oncogenes located within the amplicon. Cytogen-
etically, it appears like homogeneously staining regions (hsr) or
double minute chromosomes (dmin). In contrast to solid tumors,
genomic amplification is rarely detected in hematological
malignancies. The estimated incidence of cytogenetically
detectable gene amplification in acute myeloid leukemia
(AML) is approximately 1%. Recently, 11q23 over-representa-
tion has been described as a new cytogenetic entity in myeloid
malignancies, and in these cases, the MLL gene (11q23) was
consistently amplified. The oncogenic role of amplification in
myeloid malignancies has not been demonstrated so far,
although duplication or amplification of the MLL gene in
t-AML has been significantly associated with complex karyo-
types, deletion 5q, and prior therapy with alkylating agents.1
Van Limbergen et al2 found MLL amplification together with
5q- only in AML patients, and that was significantly associated
with an extremely short survival. In most cases, the 11q23
amplified region includes the MLL gene (11q23.3), although is
not restricted to this locus. Several studies using FISH or other
molecular techniques in patients with myeloid neoplasias (10
cases with AML, and seven cases with MDS), have allowed the
identification of the genes included in the amplified region as
dmin and/or hsr such FGF3 (11q13.1), THRSP (11q13.5), DDX6
(11q23.3), ETS1 (11q24.3) and FLI1 (11q24.3).1,3–5 Only three
cases (two AML and one MDS) have been reported to have
amplification of the 11q23–24 region not including the MLL
gene.6,7 Moreover, Zatkova et al5 found that deletions within the
amplicon 11q13–24 were a quite common event (four out of 13
patients analyzed), suggesting that duplications and inversions
affecting the 11q arm might play a role in the highly complex
variability nature of the 11q amplicons, and that other genes
with possible oncogenic potential role might be implicated in
the amplification of this region. Here, we report the clinical,
cytogenetic and molecular data of a patient with AML-M2
which presented a cryptic ins(2;11)(q3?6;q23.3) with a clonal
evolution to 11q23–q25 amplification, either on hsr(11) or on
dmin, in two divergent clones. The patient had the insertion in
all clones, even in the one with no 11q amplification, suggesting
that this rearrangement might play a role in the leukemogenic
progression, and in the amplification process.
A 81-year-old white man was admitted with a history of
syncope, weight loss, faintness and weakness, anorexia, and
diffuse muscular pain. Physical examination revealed asthenia,
cold sweat, dizziness, paleness, and pain in the left hypochon-
drium. There was no lymphadenopathy, splenomegaly, or
petechiae. His medical history included type II diabetes,
moderate kidney failure, hypertension, and the diagnosis of a
prostate adenocarcinoma 6 years before. The patient had
antidiabetic treatment and hormone therapy. A complete blood
count showed hemoglobin, 88 g/l; white blood cells, 1.7 109;
and 94 109/l platelets. Biochemical results were within normal
ranges, although creatinine was lightly elevated. Bone marrow
aspirate revealed a hypocellular marrow with 32% blasts. Blasts
were large, with irregular nucleus in a rather coarse granular
chromatin and evident nucleoli; cytoplasm was moderately
abundant and basophilic with many azurophilic, peroxidase-
positive granules; there was prominent nuclear and cytoplasmic
vacuolation, and a single Auer rod. The blast cells were positive
for markers cMPO, CD34, CD33, HLA-DR, CD11b and CD45.
He was diagnosed as having AML-M2. In accordance with the
family, the patient received palliative treatment, and he died
3 weeks after admission.
Karyotyping in a sample of the patient was done on
unstimulated short-term bone marrow (BM) cultures. Fluores-
cence in situ hybridization (FISH) was performed on BM
metaphases using six BACs located from 11q13.2 to 11q25.
The order of the probes according to the current mapping data
is: centromere –RP11-699M19 (that covers CCND1), RP11-
241D13 (ATM), RP11-635F12 (ZNF145), RP11-640N11
(GRIK4), RP11-1007G5 (ETS1), RP11-654C20 (OPCML)- telo-
mere (Figure 1a). Six BACs located on 2q36 and 2q37 were
designed to analyze the 2q region. The probes, from centromere
to telomere are: RP11-395N3 (that covers IRS1), RP11-395A23
(SP100), RP11-174L18 and RP11-400N9 (SHIP), and RP11-
275G7 and RP11-110K9 (HDAC4). The clones were obtained
from libraries from BACPAC Resources (Children’s Hospital
Oakland, Oakland, CA, USA). The probes were labeled with
Spectrum Greens and Spectrum Oranges, (Vysis, Downers
Grove, IL, USA) by nick translation and used pairwise. A
commercial probe for MLL, LSI MLL Dual Color, was used
(Vysis, Downers Grove, IL, USA). Primers were designed for
specific assays of gene expression for GRIK4 (GRIK4-F (exon
17): 50-AGCGCAAATGGTGGGAAGGA-30, and GRIK4-R (exon
19): 50-TGCGCAGCTCGGTCACCATC-30; AT: 651C) and for the
MLL gene (MLL-F (exon 3): 50-CTGCCTTTCCACTCCTTCATCT-
30, and MLL-R (exon 5): 50-TCCTGGGGTGCCTTGTTTCT-30;
AT: 601C). All reactions were carried out on BM of the patient
and on BM and PB from a healthy donor; the GRIK4 gene
expression was carried out as well on the brain cell line SK-N-
MC (American Type Culture Collection No. HTB-10), as a
positive control. Expression levels of MLL and BCR on BM cells
from the patient and from a healthy donor were compared using
the BCR gene as an internal control (BCR-F: 50-GAGAA-
GAGGGCGAACAAG-30, and BCR-R: 50-CTCTGCTTAATTC-
CAGTGGC-30). Serial dilutions of the sample from the healthy
donor were analyzed to control that all reactions were kept in
the linear phase of amplification.
G-banding on BM cells of the patient at diagnosis showed
three different clones: clone 1: 46,XY,del(5)(q31q35),þ 8,20[15],
clone 2: 46,idem,10–17dmin[3] and clone 3: 45,XY,del(5)
(q31q35),hsr(11)(q23),20[12]. This karyotype suggests that all
clones could have come from a previous one with 5q- and
monosomy 20. From this one the other clones would have
progressed: clone 1 (5q, þ 8, 20), from which would derive
clone 2 (5q-, þ 8, 20, dmin); and clone 3, that is hypodiploid
(5q-, hsr(11q), 20) (Figure 1b). Therefore, the 11q amplification
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in dmin does not derive from the clone with hsr, indicating that
the mechanism of amplification could be independent. Cyto-
genetically divergent clones could be of interest in the
discussion of the clonal evolution, and for an evaluation of the
role of different chromosome aberrations in malignant transfor-
mation and tumor progression. To our knowledge, this is the
third time that a patient showing two divergent clones contain-
ing either hsr or dmin with MLL amplification is reported.3,4
FISH experiments using the MLL probe showed amplification
of this gene in clones 2 and 3, the clones with dmin (3–17) and
hsr. To delimit the amplified region, a panel of six clones from
11q13.2 to 11q25 was chosen. The amplification spanned from
MLL, on 11q23.3 (117.8–117.9 Mb), to OPCML, on 11q25
(Figure 1a). The probes that cover MLL, ETS1, and OPCML were
amplified in both hsr and dmin, whereas there were only two
copies of the probes centromeric to MLL, including RP11-
635F12 (113.45–113.65 Mb), also located on 11q23.3. How-
ever, BAC RP11-640N11, that covers the 30 region of the GRIK4
gene, showed a different signal pattern: we detected amplifica-
tion on the dmin but not on hsr, showing the high variability in
the amplification in this region. Furthermore, with this probe an
extra signal in the long arm of chromosome 2 was found in all
three clones, even in clone 1 that had neither dmin nor hsr
(Figure 1b). To characterize the cryptic rearrangement between
chromosomes 2 and 11, we performed FISH analysis with six
probes located on 2q36–q37. The probes were found neither
deleted nor split, and no material from chromosome 2 was
found on 11q, suggesting a cryptic der(2)ins(2;11)(q3?6;
q23.3orq24?) in all malignant cells that could play a role in
the mechanism of amplification.
The precise mechanism by which gene amplification occurs
in human cancers is unknown. Experimentally, it appears that
several types of genetic abnormalities are required to allow gene
amplification to take place: loss of cell-cycle control by inacti-
vation of p53, DNA damage or instability, and some stimulus to
progress as a result of oncogene activation or other mechanisms.
Unfortunately, it is difficult to draw firm conclusions about early
events in the amplification process (reviewed in Hogarty and
Brodeur8). Some information can be obtained by structural
analysis of the amplified unit, as well as by analysis of the
genomic configuration of the locus that was amplified. In this
sense, it is useful to delimit the size of the amplicon, and the
genes involved. In our patient, the amplification was from
11q23.3 (less than 5 Mb upstream MLL) to 11q25. Interestingly,
hsr and dmin were found in two different clones, indicating
there is an independent mechanism involved, or that both
events could have derived from similar mechanisms with
different behavior during the cell cycle. As expected, in the
hsr(11q) the amplicon was arranged in tandem. The extra-
chromosomal dmins are structures that lack centromeres or
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Figure 1 FISH analysis of a patient with AML-M2. (a) A map of the region from 11q13.2 to 11q25 showing the relative position of the clones
used in this study, and the genes involved. In FISH results, the chromosome where each probe hybridizes in the three different clones is indicated.
(b) Images of FISH and G-banding metaphases of the three clones, showing the hypothetical clone progression. The probes and color used for their
detection are indicated.
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kinetochores, and it is likely that to remain stable they are closed
circular molecules.8 They apparently segregate randomly in the
two daughter cells after cell division. The mechanism of dmin
formation probably involves the duplication of a large chromo-
somal region, followed by deletion and circularization to
form dmin. The number of FISH signals we found in the dmins
(clone 2) were different depending on the probes used, there
were more signals in the more telomeric regions (Figure 1). This
suggests that the mechanism of amplification as dmin in our
patient could be the duplication and deletion of different
overlapping regions, always including the more telomeric
region. The dmin may contain amplicon of different size which
suggests additional rearrangement at the time of dmin replica-
tion, during cell cycle, with loss of sequences. That could
explain we detected more copies of the telomeric probes in
the dmin.
The only gene contained in the chromosome 11 probe that
goes to the der(2) is GRIK4 (glutamate receptor, ionotropic,
kainate 4). This gene encodes a protein that belongs to the
glutamate-gated ionic channel family, and is a major excitatory
neurotransmitter in the mammalian central nervous system,
through activation of ligand-gated ion channels and G protein-
coupled membrane receptors. This gene is highly expressed in
brain but neither in BM nor PB. To check if GRIK4 was
ectopically expressed in BM of our patient, we performed a RT-
PCR. As expected, we found a strong expression of the GRIK4
gene in the SK-N-MC brain cell line, but no expression was
detected either in normal BM, normal PB, or in the patient
sample (Figure 2a). We also performed RT-PCR on RNA from
BM cells using specific primers for MLL. This analysis showed
that the MLL gene was overexpressed in the patient as a
consequence of the amplification. Although a quantitative
analysis was not possible because there was no material left,
comparison in normal BM and in the leukemic cells, using the
BCR gene expression as a control, suggests that MLL is
overexpressed in our patient (Figure 2b). Therefore, overexpres-
sion of MLL, but not the ectopic expression of GRIK4, could
have contributed to the leukemic transformation in this
patient, and not all genes contained in the amplicon were
overexpressed.
In conclusion, we report the analysis of a patient with AML-
M2 and amplification of the 11q23–q25 region on dmin and
hsr in two divergent clones. Our analysis revealed that the
amplified region was not restricted to the MLL gene, but
spanned from 11q23.3 to 11q25. The probe RP11-640N11, that
covers the GRIK4 gene, was amplified in the dmin, but not in
the clone with hsr, and was inserted on 2q36 in all clones
analyzed. Molecular analysis showed that MLL, but not GRIK4
was overexpressed in the patient. These results suggest that
the process of gene amplification might be based on initial
structural aberrations affecting the 11q arm that could have a
role in the progression. The biological significance of the two
mechanisms of amplification in the disease process remains to
be elucidated.
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TO THE EDITOR
In multiple myeloma (MM) patients, treatment with thalidomide
has proven its efficacy as monotherapy, but also combined with
dexamethasone and chemotherapy. However, in combination
with these drugs thalidomide may increase the incidence of
deep venous thrombosis and pulmonary embolism up to 30%.1
The pathogenesis of these thrombotic events is
poorly understood and it is also not known how to prevent
thalidomide-associated venous thromboembolism (VTE).2
In patients who were treated in the prospective, multicenter
phase III HOVON-50/GMMH-HD3 study, we evaluated the
incidence of VTE in newly diagnosed MM patients during
induction therapy with thalidomide, doxorubicin and dexa-
methasone when using the low molecular-weight heparin
(LMWH) nadroparine in prophylaxis dosage.
Patients, age 18–65 years, with newly diagnosed MM,
Salmon & Durie stage II or III, were eligible for inclusion.
Informed consent was obtained from all patients. According
to the Declaration of Helsinki, the protocol was approved
by the Research Ethics Board of each participating hospital.
Patients were randomly assigned to induction chemotherapy
consisting of three cycles of vincristine (0.4 mg, i.v. on days
1–4), doxorubicin (9 mg/m2, i.v. on days 1–4) and dexametha-
sone 40 mg orally (days 1–4, 9–12, 17–20), (VAD) arm A.
Patients assigned to arm B received thalidomide instead
of vincristine (TAD). Cycle 2 starts at day 29, cycle 3 at day
57. Thalidomide was given as 200 mg orally, starting at day 1 of
the first TAD cycle and was stopped 2 weeks before
chemotherapy for stem cell mobilization was started. The
thalidomide dose could be escalated to maximally 400 mg in
case of good tolerability. Patients in arm B started with standard
dosage thrombosis prophylaxis consisting of subcutaneously
LMWH nadroparine 2850 IE anti-Xa or 5700 anti-Xa in case of
weight above 90 kg. Prophylaxis was started at day 1 of the first
TAD cycle until 1 week before start of chemotherapy for stem
cell mobilization. Stem cells were mobilized after cyclopho-
sphamide 1000 mg/m2 i.v. day 1, doxorubicin 15 mg/m2, i.v. on
days 1–4, dexamethasone 40 mg orally on days 1–4 (CAD) and
G-CSF 5 mg/kg twice daily until collection. After induction
therapy all patients received one or two courses of high-dose
melphalan (HDM) 200 mg/m2 with autologous stem cell rescue.
Patients randomized to arm A received maintenance therapy
with a-interferon (3 106 IU, thrice weekly) and patients
randomized to arm B received thalidomide 50 mg/day without
VTE prophylaxis.
The incidence of VTE was a secondary end point of the study
and had to be reported directly by fax to the datacenters as a
serious adverse event. The reporting hospitals were then
contacted for further details. As control a separate questionnaire
was sent to all participating hospitals.
All types of venous thrombosis and pulmonary embolism
were included and diagnosis was made by Doppler ultrasono-
graphy or spiral pulmonary computer tomography.
The time to occurrence of the first VTE, TVTE , was calculated
from the date of randomization. Patients who died within
6 months without VTE were censored at the date of death. TVTE
was estimated with the actuarial method of Kaplan and Meier
and 95% confidence intervals were calculated, Kaplan–Meier
curves of TVTE were generated to illustrate differences between
the two treatment arms, and the log-rank test was used to
compare the two curves. The reported P-values are two-sided,
and a significance level of a¼ 0.05 was used.
Inclusion started in November 2001 and as of May 1, 2003,
412 patients were included, 201 patients in Arm A and 211
patients in Arm B. The data were analyzed as of January 16,
2004.
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